Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical spironolactone 5% versus topical progesterone 2% for female pattern hair loss
IRCT201512252581N4Phase 4Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of spironolactone and progesterone in Female Pattern Hair Loss (FPHL) and androgenetic alopecia (AGA) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Hair density and Hair diameter. Started Dec 2015; status: completed.
02
Drugs
spironolactoneprogesterone
03
Conditions
Female Pattern Hair Loss (FPHL)androgenetic alopecia (AGA)
Beyond the preview
Go deeper on IRCT201512252581N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201512252581N4.